



(51) International Patent Classification:

C07D 405/06 (2006.01) *A61K 31/501* (2006.01)
A61K 31/495 (2006.01) *A61P 17/06* (2006.01)
A61K 31/496 (2006.01) *A61P 37/00* (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/CN2015/079755

(22) International Filing Date:

26 May 2015 (26.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2014/078701 28 May 2014 (28.05.2014) CN

(71) Applicant: **GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED** [GB/GB]; 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(71) Applicant (*for PG only*): **GLAXOSMITHKLINE (CHINA) R&D COMPANY LIMITED** [CN/CN]; Building 3, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **LEI, Hui**; GlaxoSmithKline (China) R&D Co., Ltd., Building 3, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN). **MA, Xin**; GlaxoSmithKline (China) R&D Co., Ltd., Building 3, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN). **REN, Feng**; GlaxoSmithKline (China) R&D Co., Ltd., Building 3, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN). **LIN, Xichen**; GlaxoSmithKline (China) R&D Co., Ltd., Building 3, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN). **MARQUIS, Robert W., Jr.**; 1250 South Collegeville Road, Collegeville, PA Pennsylvania 19426 (US).

(74) Agent: **KING & WOOD MALLESONS**; 20th Floor, East Tower, World Financial Centre, No.1 Dongsanhuan Zhonglu, Chaoyang District, Beijing 100020 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The present invention relates to novel retinoid-related orphan receptor gamma(ROR γ)modulators and their use in the treatment of diseases mediated by ROR γ .

